Connect with us

Health

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

Published

on

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

NEWYou can now listen to Fox News articles!

Scientists have created a new antibody treatment that helps the immune system recognize and attack pancreatic cancer.

Pancreatic cancer cells use a sugary “disguise” to trick the immune system into ignoring them.

Most current cancer immunotherapies target proteins or genes, but this new therapy focuses on the sugars on the cell surface, blocking them so that immune cells can find and attack the cancer, according to researchers from Northwestern University in Chicago.

CANCER VACCINE SHOWS PROMISE IN PREVENTING RECURRENCE OF PANCREATIC, COLORECTAL TUMORS

Advertisement

“Pancreatic cancer is notoriously good at hiding from the immune system, but we were struck that a single sugar, called sialic acid, can so powerfully fool immune cells,” senior author Mohamed Abdel-Mohsen, associate professor of medicine in the division of infectious diseases at Northwestern University Feinberg School of Medicine, told Fox News Digital. 

“When tumors sugar-coat themselves with this molecule, it flips an immune ‘off switch’ on certain immune cells, essentially signaling, ‘I’m a normal, healthy cell; don’t attack.’”

Study authors Mohamed Abdel-Mohsen (top) and Pratima Saini (foreground) are pictured in Abdel-Mohsen’s lab. (Northwestern University)

In mice studies, the therapy was shown to be successful in blocking this sugar signal, “waking up” immune cells and slowing cancer’s growth.

In two mouse models, tumors treated with the antibody grew significantly slower than groups that did not receive the treatment, the study showed.

Advertisement

CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY

These findings could pave the way toward testing in human groups, and could potentially be combined with chemotherapy and existing immunotherapies, according to the researchers.

The findings were published in the journal Cancer Research on Nov. 3.

Study senior author Mohamed Abdel-Mohsen is shown in his lab. “This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” he said. (Northwestern University)

“This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” said Abdel-Mohson.

Advertisement

Heloisa P. Soares, M.D., Ph.D., medical director of theranostics at Huntsman Cancer Institute and associate professor of internal medicine at the University of Utah, said this research is “encouraging” because it points to a new way of helping the immune system recognize and fight pancreatic cancer.

“Pancreatic cancer is notoriously good at hiding from the immune system.”

“It was surprising to learn that a protein usually responsible for helping cells stick together is also being used by pancreatic cancer as a hidden ‘do-not-attack’ signal,” Soares, who was not involved in the study, told Fox News Digital.

“The striking part was that when this signal was blocked, the immune cells woke back up and started attacking the tumor much more effectively — which suggests a promising new direction for treatment.”

CANCER TREATMENT COULD BE LESS EFFECTIVE IF PATIENTS CONSUME POPULAR SWEETENER

Advertisement

Pancreatic cancer is one of the most lethal forms of the disease. It’s usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%, the researchers noted.

Unlike many other cancers, it often doesn’t respond to immunotherapy.

Pancreatic cancer is usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%. (iStock)

“Pancreatic cancer is often diagnosed late, in part because it remains asymptomatic and is deep in the body,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital.

“It is also difficult to treat because it doesn’t have many good immune targets and doesn’t mutate that much.”

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The study did have some limitations, the researchers acknowledged — primarily that the tests have only been conducted on animals thus far and there is not yet any human data.

“Animal models cannot capture all the complexity of human pancreatic cancer,” the lead researcher noted. “Tumors also use multiple escape routes, so this strategy will likely be part of a combination approach.”

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients. (Northwestern University)

The long-term safety and dosing parameters of the therapy are also unknown.

Advertisement

“We need clinical trials to see how effective this is in humans and whether it has a role in cancer treatments for this difficult and deadly cancer — but it is quite promising,” Siegel added.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The research team is now working with clinicians at Northwestern’s Robert H. Lurie Comprehensive Cancer Center on next steps toward potential human studies, likely in combination with current chemotherapy and immunotherapies, according to Abdel-Mohsen.

“It’s a promising step forward, but not something that will change care overnight.”

“If future studies support it, this approach could be added to the toolbox against pancreatic cancer, likely alongside existing chemo-immunotherapy, not replacing what’s working today,” he told Fox News Digital.

Advertisement

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Soares added, “It’s a promising step forward, but not something that will change care overnight. Continued funding and participation in clinical trials are essential to keep this progress moving.”

CLICK HERE FOR MORE HEALTH STORIES

The study was supported in part by the National Institutes of Health.

Advertisement

Health

Scientists pinpoint why COVID vaccine may trigger heart inflammation in certain people

Published

on

Scientists pinpoint why COVID vaccine may trigger heart inflammation in certain people

NEWYou can now listen to Fox News articles!

POST-DOSE PATTERN — New research reveals why the COVID vaccine can trigger heart issues, especially in one group

PREVENTION PAYOFF — Simple lifestyle changes could slash heart attack risk for millions

A new study has identified why mRNA COVID-19 vaccines could trigger heart issues, especially in one demographic. (iStock)

SMOKE SCREEN — A major cannabis study finds little proof for popular medical claims and flags big dangers

Advertisement

HIDDEN LINK — A common dental health issue may hint at a dangerous cardiovascular condition

SIGN UP FOR OUR HEALTH NEWSLETTER

SCREENING DEBATE A new study questions whether annual mammograms are necessary for most women

SUPER SPREAD — An “aggressive” new flu variant sweeps the globe as doctors warn of severe symptoms

The flu season has intensified as the new H3N2 variant causes severe illness worldwide. (iStock)

Advertisement

DANGEROUS DEFICIT — A nutrient deficiency has been linked to heart disease risk for millions

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE HEALTH NEWS

CORONARY CHRISTMAS — Holiday heart attacks spike as doctors share hidden triggers and prevention tips

Continue Reading

Health

Aging-related joint disorder increasingly affects people under 40, study finds

Published

on

Aging-related joint disorder increasingly affects people under 40, study finds

NEWYou can now listen to Fox News articles!

Cases of gout are rising in younger individuals, according to a global study.

The condition, which is a type of inflammatory arthritis, steadily increased in people aged 15 to 39 between 1990 and 2021, researchers in China announced.

Although rates vary widely between countries, the total number of young people with the condition is expected to continue rising through 2035.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

Advertisement

The study, published in the journal Joint Bone Spine, investigated 2021 data from the Global Burden of Disease (GBD), spanning 204 countries within the 30-year timeframe.

The data measured gout prevalence, incidence and years lived with disability, tracking global trends over time. The results showed a global increase across all three outcomes.

Gout is expected to continue rising in young people through 2035. (iStock)

Prevalence and disability years increased by 66%, and incidence rose by 62%. In 2021, 15- to 39-year-olds accounted for nearly 14% of new gout cases globally, the study found.

Men from 35 to 39 years old and people in high-income regions had the highest burden, but high-income North America topped the list for highest rates.

Advertisement

‘SKINNY FAT’ WARNING ISSUED AS STUDY FINDS HIDDEN OBESITY BEHIND NORMAL BMI

Men were also found to have lived more years with gout due to high BMI, while women tended to have the condition as a link to kidney dysfunction, the study noted.

The total number of cases is expected to increase globally due to population growth, but the study projected that rates per population would decrease.

The researchers noted that data quality, especially in low-income settings, could have posed a limitation to the broad GBD data.

What is gout?

Gout is a common form of arthritis involving sudden and severe attacks of pain, swelling, redness and tenderness in the joints, according to Mayo Clinic. It most often occurs in the big toe.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The condition occurs when urate crystals accumulate in the joint. These form when there are high levels of uric acid in the blood, which the body produces when it breaks down a natural substance called purines.

A gout flare-up can happen at any time, often at night, causing the affected joint to feel hot, swollen, tender and sensitive to the touch.

Urate crystals, described as sharp and needle-like, build up in the joint, causing intense pain and swelling. (iStock)

Purines can also be found in certain foods, like red meat or organ meats like liver and some seafood, including anchovies, sardines, mussels, scallops, trout and tuna, according to the Mayo Clinic. Alcoholic drinks, especially beer, and drinks sweetened with fruit sugar can also lead to higher uric acid levels.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Uric acid will typically dissolve in the blood and pass through the kidneys into urine, but when the body produces too much or too little uric acid, it can cause a build-up of urate crystals. These are described by the Mayo Clinic as sharp and needle-like, causing pain, inflammation and swelling in the joint or surrounding tissue.

Risk factors for gout include a diet rich in high-purine foods and being overweight, which causes the body to produce more uric acid and the kidneys to have trouble eliminating it.

Experts urge patients to seek medical attention for gout flare-ups. (iStock)

Certain conditions like untreated high blood pressure, diabetes, obesity, metabolic syndrome and heart and kidney diseases can increase the risk of gout, as well as certain medications.

Advertisement

A family history of gout can also increase risk. Men are more likely to develop the condition, as women tend to have lower uric acid levels, although symptoms generally develop after menopause.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Untreated gout can cause worsening pain and joint damage, experts caution. It may also lead to more severe conditions, such as recurrent gout, advanced gout and kidney stones.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The Mayo Clinic advises patients to seek immediate medical care if a fever occurs or if a joint becomes hot and inflamed, which is a sign of infection. Certain anti-inflammatory medications can help treat gout flares and complications.

Advertisement

Fox News Digital reached out to the researchers for comment.

Continue Reading

Health

New study questions whether annual mammograms are necessary for most women

Published

on

New study questions whether annual mammograms are necessary for most women

NEWYou can now listen to Fox News articles!

A new study suggests that annual mammograms may not be the only effective approach for preventing breast cancer.

The research, published in the Journal of the American Medical Association (JAMA), tested a risk-based breast cancer screening approach against standard annual mammography.

The WISDOM randomized clinical trial, led by study authors from universities and healthcare systems across the U.S., considered more than 28,000 women aged 40 to 74 years old, splitting them into a risk-based screening group and an annual mammography group.

ERIN ANDREWS HAD ‘NO SYMPTOMS’ BEFORE CANCER DIAGNOSIS, PUSHES FOR EARLY SCREENINGS

Advertisement

Researchers calculated each woman’s individual risk based on genetics (sequencing of nine breast cancer genes) and other health factors. 

A new study suggests that annual mammograms may not be the only effective approach for preventing breast cancer. (iStock)

Those who were at the highest risk were advised to alternate between a mammogram and an MRI scan every six months. Patients with elevated risk were told to get an annual mammography and counseling.

Average-risk women were guided to get mammograms every two years, while low-risk individuals were advised to have no screening until they became higher risk or reached age 50.

HIDDEN TYPE OF BREAST CANCER COULD BE EXPOSED BY NEW BREAKTHROUGH TECH

Advertisement

The researchers found that risk-based screening did not lead to more advanced cancer diagnoses (stage 2B or higher) compared with annual screening, indicating that it is just as safe as traditional methods. The risk-based approach, however, did not reduce the number of biopsies overall, as researchers had hoped.

Among the risk-based group of women, those with higher risk had more screening, biopsies and detected cancers. Women at lower risk had fewer procedures.

The research, published in the Journal of the American Medical Association (JAMA), tested a risk-based breast cancer screening approach against standard annual mammography. (iStock)

“[The] findings suggest that risk-based breast cancer screening is a safe alternative to annual screening for women aged 40 to 74 years,” the researchers noted in the research summary. “Screening intensity matched individual risk, potentially reducing unnecessary imaging.”

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

Fox News medical contributor Dr. Nicole Saphier, associate professor of radiology at Memorial Sloan Kettering Cancer Center in New Jersey, commented that while these findings are important, the study “completely sidelines” what screenings are designed to do — detect cancer early.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“If you don’t measure stage 0, stage 1 or stage 2A cancers, you can’t tell whether personalized screening delays diagnosis in a way that matters for survival and treatment intensity,” Saphier, who was not involved in the study, told Fox News Digital in an interview.

Those who were at the highest risk were advised to alternate between a mammogram and an MRI scan every six months. (iStock)

More than 60% of breast cancers in the U.S. are diagnosed at stage 1 or 2A, where cure rates exceed 90%, the doctor noted.

Advertisement

The trial doesn’t “fully evaluate” whether risk-based screening changes detection at the earliest and most treatable stages, where screening “delivers its greatest benefit,” according to Saphier.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Mammography is not without risk — radiation exposure, false positives, anxiety and potential over-diagnosis are real and should be acknowledged,” she said. “But it remains the most effective, evidence-based tool for detecting breast cancer early, when treatment is most successful.”

The expert added that labeling women under 50 as “low risk” is “outdated,” as breast cancer diagnoses are on the rise in younger females.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

“Until long-term mortality data support alternative approaches, annual screening beginning at 40 for average risk women should continue,” Saphier added. “Women should be assessed for breast cancer risk by 25 years old to determine if screening should begin earlier.”

Continue Reading
Advertisement

Trending